Adage Capital Partners
VRDN icon

Adage Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

Adage Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-970,018
Closed -$19M – 1096
2026
Q1 		$19M Buy
970,018
+180,000
+23% +$5.35M 0.03% 478
2025
Q4 		$24.6M Sell
790,018
-430,110
-35% -$11.8M 0.04% 421
2025
Q3 		$26.3M Buy
1,220,128
+111,542
+10% +$2.01M 0.04% 389
2025
Q2 		$15.5M Sell
1,108,586
-6,000
-0.5% -$81.4K 0.03% 509
2025
Q1 		$15M Sell
1,114,586
-555,414
-33% -$9.46M 0.03% 484
2024
Q4 		$32M Buy
1,670,000
+465,000
+39% +$10.1M 0.06% 311
2024
Q3 		$27.4M Buy
+1,205,000
New +$19.7M 0.05% 371

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Adage Capital Partners's VRDN Position: Q2 2026 in Review

Adage Capital Partners sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 970,018 shares — an estimated $19M sold.

Adage Capital Partners first reported a position in VRDN in Q3 2024 and held it in 7 quarters. The position peaked at $32M in Q4 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Adage Capital Partners reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Adage Capital Partners sold 970,018 Viridian Therapeutics shares in Q2 2026, an estimated $19M.
  • Adage Capital Partners first reported a position in Viridian Therapeutics in Q3 2024 and held it in 7 quarters.
  • Adage Capital Partners's Viridian Therapeutics position peaked at $32M in Q4 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.